Moderna Inc. (MRNA)
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MRNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $78.90B
- EPS (TTM)
- -$7.04
- Dividend yield
- None
- 52-week range
- 23.55 – 280.80
- Day range
- 191.46 – 210.00
- Volume / Avg
- 9.66M / 16.52M
- Beta
- —
- Shares outstanding
- 404.62M
52-week range
MRNA stock today
Shares of Moderna (MRNA) finished lower on Nov 20 at $195.00, a drop of 2.17% or $4.33 per share, versus the S&P 500's 3.70% decline. At this level, MRNA sits in the middle of its 52-week range of $23.55 to $280.80: 30.6% below the high, set on Nov 9, 2026 and 728.2% above the low. MRNA is up 561.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 722.1%.
Moderna has posted a net loss over the last twelve months (EPS of -$7.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Moderna
Company profileModerna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Stéphane Bancel M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 4,700
- IPO year
- 2018
- Website
- modernatx.com
Financial highlights
Full financialsIn fiscal 2025, Moderna generated $1.94 billion in revenue, down 39.9% from fiscal 2024, its first annual decline since 2024. Moderna reported a net loss of $2.82 billion, compared with a loss of $3.56 billion a year earlier. Gross margin was 55.3% (up from 54.8%) and operating margin -158.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Growth | -39.93% | -52.75% | -64.45% | +4.29% | +2200.25% |
| Net income | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B |
| EPS (diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
Analyst forecast
ForecastConsensus (23 analysts)
hold
Avg. price target
$165.32-15.22%
- Strong buy 1
- Buy 3
- Hold 16
- Sell 2
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $0.38 vs $-1.10
- Surprise
- +134.55%
MRNA news
All MRNA news- 1 High-Flying Stock to Buy Hand Over Fist if the Stock Market CrashesNasdaqMRNA, LEN.B
- Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027NasdaqMRNA, MRK, BMY, BNTX
- Healthcare ETFs Shine as Investors Rotate Out of TechNasdaqLLY, MRNA, XLV, BBH
- Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?NasdaqMRNA, PFE, MRK, BNTX
- While Moderna sank 17%, this generic drugmaker quietly jumped 64%Investing.com
- Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.NasdaqMRNA, MRK
- Moderna 600% YTD rally catches cold: What's next amid stock's downtrend?Seeking Alpha
- Moderna drops marking longest losing streak since 2024Seeking Alpha
Moderna peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARGXargenx SE ADR | 925.70 | -1.73% | $58.21B | vs MRNA |
| BIIBBiogen Inc. | 249.59 | +1.00% | $36.89B | vs MRNA |
| RVMDRevolution Medicines Inc. | 161.20 | +1.11% | $34.87B | vs MRNA |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs MRNA |
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs MRNA |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs MRNA |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs MRNA |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs MRNA |
Indexes, lists and sector
Index membership
Moderna stock FAQ
What is Moderna's stock price today?
MRNA last traded at $195.00 as of Nov 20, 4:00 PM EST, down 2.17% on the day. Prices are delayed at least 15 minutes.
Is Moderna in the S&P 500?
Yes. Moderna (MRNA) is a constituent of the S&P 500 index.
Who is Moderna's CEO?
Mr. Stéphane Bancel M.B.A. is the chief executive officer of Moderna Inc., which has about 4,700 employees.
What is the MRNA 52-week high?
The 52-week high for MRNA is $280.80 and the 52-week low is $23.55. The stock is currently 30.6% below its high.